This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 provides funding for Beken Bio, Inc. to develop a highly sensitive, minimally invasive laboratory test to detect early-stage ovarian cancers. The project aims to identify and engineer an assay to differentiate relevant biomarkers on circulating extracellular vesicles in patient plasma, with the goal of achieving high specificity in diagnosing malignant tumors. The technology will also employ machine learning to provide actionable diagnostic information to clinicians. Successful completion of this Phase I effort would facilitate the development and validation of scalable workflows for the diagnostic assay during a future Phase II, with the intent of commercializing a laboratory-developed test. This award reflects NSF's mission to advance scientific research and technological innovation with the potential for significant societal and economic impact.
Generated 2/25/25, 5:30 AM